NEXGEL Reports Stellar Financial Growth for Q2
NEXGEL, Inc. (NASDAQ: NXGL), a prominent provider of healthcare and beauty products, has announced its financial results for the second quarter of 2025. In an impressive turn, the company has reported a doubling of revenue to $2.88 million compared to $1.44 million in the same quarter last year. This remarkable 100.3% increase underscores NEXGEL's growing market presence and the effectiveness of its product strategies.
Key Financial Highlights
For the second quarter ending June 30, 2025, NEXGEL reported a gross profit of $1.26 million, indicating a gross profit margin of 43.6%, significantly higher than 20.3% for the same period in 2024. This growth reflects the successful integration of their branded products and a surge in consumer demand.
The company's net loss for this quarter was $0.67 million, an improvement from a net loss of $0.89 million recorded in the same quarter last year. Furthermore, NEXGEL anticipates positive EBITDA for the fiscal year 2025, with guidance set at $13 million in revenue.
Management Comments
Adam Levy, Chief Executive Officer of NEXGEL, expressed optimism about the ongoing growth trajectory, stating, "The year-over-year growth was fueled by our innovative consumer product offerings and new contracts in our manufacturing division. As we approach the latter half of the year, we foresee even greater opportunities for expansion with several product launches lined up and additional contract manufacturing clients joining our portfolio."
Operational Developments
During the quarter, NEXGEL successfully closed a financing deal generating approximately $1.05 million in gross proceeds, which will support its growth initiatives. Additionally, they expanded their partnership with STADA, which included a $1 million advance to bolster its product launches and marketing strategies.
This strategic approach, alongside new consumer product launches and a strong pipeline of contract manufacturing clients, reinforces NEXGEL's commitment to expanding its market share and enhancing brand recognition.
Financial Results Overview
NEXGEL's financial records indicate an ongoing positive trend across various metrics, with their net revenue for Q2 of 2025 being $2.88 million, up from $1.44 million in Q2 2024 and a significant improvement over $2.81 million in Q1 2025.
As of June 30, 2025, the company reported current assets totaling $4.16 million while its cash balance stood at approximately $0.73 million. This strong asset base positions NEXGEL favorably for future growth pursuits.
Looking Ahead
NEXGEL remains focused on its growth trajectory in the health and beauty space. The company is poised to continue building on its strengths with anticipated product launches and strategic partnerships. With a robust pipeline and a clear vision for the future, NEXGEL is well-equipped to achieve its financial goals for 2025 and beyond.
Frequently Asked Questions
What were NEXGEL's revenue results for Q2 2025?
NEXGEL reported $2.88 million in revenue for Q2 2025, a 100.3% increase year-over-year.
How does NEXGEL's gross profit margin compare to last year?
The gross profit margin for Q2 2025 was 43.6%, compared to 20.3% for the same period in 2024.
What is the company's outlook for the remainder of 2025?
NEXGEL expects to achieve $13 million in revenue and positive EBITDA by the end of 2025.
What strategic partnerships is NEXGEL involved in?
NEXGEL has expanded its partnership with STADA, including a $1 million advance to support new product launches.
What products does NEXGEL provide?
NEXGEL offers a variety of healthcare and beauty products, including high-water-content hydrogel products suited for consumer applications.
